2. Because many enterprises have won the bid for most basic drugs of the same variety, hospitals have the right to choose, so they have the ability to ask for kickbacks and kickbacks, and the winning pharmaceutical companies know this well, so they must reserve space for kickbacks and kickbacks in the bidding price. This kind of drug procurement and sales model is just a simple copy of the previous public hospital drug procurement and sales model and the government centralized bidding and procurement model. Pharmaceutical companies are familiar with this, and health centers have long heard about it. The two sides are completely in tune and hit it off. Therefore, after the implementation of the zero price difference system, the hospital mainly considers the rebate and the level of rebate, and the quality of drugs is basically not considered by the hospital, because the government chooses the quality through centralized bidding. In other words, as long as the winning drugs are purchased, even if there are quality problems, it should be the bidding agency rather than the health center. Moreover, hospitals and their doctors have no ability to judge the quality of drugs, especially the basic drugs that have not been used before.
Three. Because hospital doctors and rural doctors will lose a lot after zero price difference management, hospital doctors have no kickbacks and gray income, but the dean and some leaders who purchase drugs can get more kickbacks. Doctors may lack enthusiasm, and a large number of public doctors will jump to private hospitals and open their own private clinics. In particular, rural doctors will also have a large number of job-hopping or illegal drug use. Because the income of state subsidies is far less than that of private enterprises, more health records are needed.